Starting July 1, any health care entity or private equity firm that is planning a merger or acquisition in Indiana—where the assets of at least one of the parties is $10 million or more—must notify the state attorney general at least 90 days in advance.
Longtime business partners Robert Laikin and Larry Paulson, who made their fortunes in the cellphone industry, are turning their sights to manufacturing high-density batteries for industrial uses.
Anat Ashkenazi was Lilly’s third-highest paid executive last year. She has worked at the company for 23 years, including as chief financial officer since 2021.
James Lin, a biomedical researcher who has focused on new innovations for tissue engineering and regenerative medicine, will start his new job in Indianapolis on Aug. 26.
The 425,000-square-foot project will mark the Indianapolis-based health care system’s first hospital in Hamilton County.
Lilly plans to outfit its Lebanon plants—now under construction—with the latest in robotic, digital manufacturing equipment that will do much of the work that a generation ago was done by humans.
Eli Lilly and Co. plans to build the center on an existing parking lot at its downtown campus, with the goal of hosting more of its global meetings in Indianapolis.
Elanco has called Bovaer a potential blockbuster, meaning it could ring up annual sales of at least $100 million.
The company said the site footprint will not expand, but the company will fill in the property with more buildings and equipment. Manufacturing capacity will almost triple there.
Lilly said the new investment will allow it to hire 200 more workers at the complex, including engineers, scientists, and lab technicians, for a total of 900 full-time workers when it is fully operational.
Novartis Manufacturing LLC told a committee of the City-County Council on Monday evening that it plans to spend up to $125 million to construct and equip a 79,000-square-foot-building for radiopharmaceutical manufacturing and distribution on the city’s west side.
The Indiana Board of Nursing has accredited the university to accept 48 students a year, meaning the program will have nearly 200 students when it is fully enrolled across four years.
The roster of radiopharmaceuticals players in the Indianapolis area has surged in the past few years to include some of the world’s leading pharmaceutical companies, attracted by the potential for significant growth.
In a series of lawsuits Lilly filed in September and October in federal court, the drugmaker had accused Totality Medispa of trademark infringement, false advertising, unfair competition and unfair trade practices.
The U.S. Food and Drug Administration is convening a panel of independent experts on June 10 to discuss donanemab’s safety and effectiveness, including the results in patients in a clinical trial.
In response, Indiana Hospital Association President Brian Tabor said the Rand report “continues to paint a distorted view of health care in our state.”
For the first time, federal regulations will cover the nearly 50 dumps spread across 14 locations in Indiana that were previously exempted from cleanup provisions.
A report issued Monday by BioCrossroads says Indiana life sciences companies saw a decrease in capital and investments last year, but made a significantly higher contribution to the state’s economy than they did the previous year.
Lilly’s newest obesity and diabetes medicines, widely known as GLP-1 drugs, are drawing rave reviews from doctors, researchers and patients for their ability to safely and effectively control blood sugar and take off weight.
The Carmel medical group is gaining a reputation as a training and education center. It holds courses for high school and college students in anatomy as well as surgeons going out on their own after residencies and fellowships.
